During the past decade, National Hospital Organization Hokkaido Cancer Center conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 20 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 14 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Hospital Organization Hokkaido Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Pfizer" with 14 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Japan Clinical Oncology Group" with 3 trials sponsored and "Puma Biotechnology, Inc." with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Hospital Organization Hokkaido Cancer Center" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 5 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Korean Cancer Study Group" with 2 trials as a collaborator and "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "National Hospital Organization Hokkaido Cancer Center" are "Breast Cancer" (7 trials), "Breast Neoplasms" (7 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials), "Neoplasms" (3 trials) and "Early Breast Cancer" (2 trials). Many other conditions were trialed in "National Hospital Organization Hokkaido Cancer Center" in a lesser frequency.

Most popular intervention types in "National Hospital Organization Hokkaido Cancer Center" are "Drug" (58 trials), "Other" (4 trials), "Procedure" (3 trials), "Device" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (8 trials), "Placebo" (8 trials), "Carboplatin" (5 trials), "Cisplatin" (5 trials) and "Docetaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "National Hospital Organization Hokkaido Cancer Center" are 50 trials for "All" genders, 8 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "National Hospital Organization Hokkaido Cancer Center". undefined are not yet recruiting, 8 are recruiting, 29 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in National Hospital Organization Hokkaido Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in National Hospital Organization Hokkaido Cancer Center, 9 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".